{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-009243","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.458380+00:00","generated_at":"2026-05-25T17:09:21.637271+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Ocugen posts corporate presentation with clinical data; 6-month treated/untreated rates shown","bullets":["Presentation shows 52% vs 44% for treated and untreated eyes at 6-month timeline.","Data likely from OCU400 gene therapy program for retinitis pigmentosa.","Presentation posted on company website March 3, 2025; used for investor discussions.","No formal guidance or regulatory update provided in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-009243","json":"https://secwatch.observer/filing/0001628280-25-009243.json","markdown":"https://secwatch.observer/filing/0001628280-25-009243.md","text":"https://secwatch.observer/filing/0001628280-25-009243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828025009243/0001628280-25-009243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828025009243/ocgn-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T17:09:21.637271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}